Since gaining independence in 1947, India has made substantial progress in healthcare delivery, pharmaceutical manufacturing, and generic drug production. However, the country has contributed relatively few novel chemical entities (NCEs) to global drug discovery. This paper examines structural, economic, institutional, and policy-related factors that have historically constrained India’s ability to innovate in original drug discovery, while also highlighting emerging opportunities for transformation.

India is widely recognized as the “pharmacy of the developing world,” owing to its robust generic pharmaceutical industry and capacity for cost-effective drug manufacturing. Despite this strength, the discovery of new molecular entities particularly first in class drugs has remained limited. Understanding this disparity requires an examination of historical policy frameworks, research ecosystems, funding structures, and industry academia dynamics.

Historical Policy Orientation (1,2)

In the decades following independence, India prioritized self-reliance in medicine access rather than innovation. The Indian Patents Act of 1970 abolished product patents for pharmaceuticals, allowing only process patents. This policy enabled domestic companies to reverse-engineer patented drugs and manufacture them at lower costs. While this significantly improved drug affordability and access, it disincentivized investment in high-risk, long-term research required for new molecule discovery.

Economic and Funding Constraints

Drug discovery is capital-intensive, often requiring billions of dollars and over a decade of sustained investment. Historically, India’s public and private sectors have allocated limited funding to basic and translational biomedical research. Government R&D expenditure as a percentage of GDP has remained relatively low compared to innovation-driven economies. Private pharmaceutical firms, focused on generics and contract manufacturing, have been reluctant to invest heavily in uncertain, high risk discovery pipelines (3,4).

Weak Industry-Academia Collaboration

A major limitation has been the disconnect between academic research institutions and the pharmaceutical industry. Academic research in India has traditionally emphasized theoretical output and publications rather than translational outcomes (5,6). Conversely, industry has focused on short-term commercial viability. The absence of strong collaborative frameworks, technology transfer mechanisms, and interdisciplinary research culture has hindered the progression of laboratory findings into viable drug candidates.

Infrastructure and Talent Utilization

Although India produces a large number of scientists and engineers, the ecosystem for advanced drug discovery such as high-throughput screening facilities, medicinal chemistry platforms (7,8), and clinical trial infrastructure has historically been underdeveloped. Brain drain has further exacerbated this issue, with many highly trained researchers migrating to countries offering better funding, infrastructure, and research freedom.

Regulatory and Institutional Challenges

Regulatory processes in India have often been perceived as complex, slow, and inconsistent. Clinical trial regulations, in particular, underwent periods of uncertainty, which discouraged both domestic and international investment in innovative drug development (9,10). Additionally, limited coordination among regulatory bodies, research institutions, and funding agencies has contributed to inefficiencies in the innovation pipeline.

Risk Averse Industrial Culture

The Indian pharmaceutical industry has largely thrived on a business model centered around generics, biosimilars, and contract research. This model offers predictable returns with lower risk compared to novel drug discovery. Consequently, companies have historically avoided investing in original research, which carries high failure rates and uncertain profitability (11,12).

Global Competition and Late Entry (13,14)

India entered the global innovation race relatively late. By the time economic liberalization occurred in the 1990s and product patents were reinstated in 2005 (in compliance with TRIPS agreements) (15,16), multinational pharmaceutical companies had already established strong dominance in drug discovery. Catching up in such a competitive and resource-intensive domain has proven challenging.

Emerging Opportunities and Recent Progress (17,18)

Despite these challenges, the landscape is evolving. Increased government initiatives, such as biotechnology missions and innovation funds, are supporting early-stage research. Indian startups and biotech firms are beginning to explore novel therapeutics, including biologics and precision medicine. Improvements in digital infrastructure, artificial intelligence (19,20), and global collaborations are also enhancing research capabilities. Furthermore, policy reforms aimed at strengthening intellectual property protection and easing clinical trial regulations are gradually improving the innovation environment. Some Indian companies have initiated NCE research programs, though large-scale success remains limited.

India’s limited contribution to novel medical chemical entities since independence is not due to a lack of scientific capability, but rather the result of historical policy choices, economic constraints, institutional fragmentation, and risk-averse industry practices. While the generics-focused model has delivered immense public health benefits globally, transitioning toward innovation-driven drug discovery requires sustained investment, systemic reforms, and cultural shifts within academia and industry. To achieve this transformation, India must strengthen research funding, foster industry-academia partnerships, streamline regulatory frameworks, and incentivize high-risk innovation. With its growing scientific talent pool and expanding biotech ecosystem, India has the potential to become a significant contributor to global drug discovery in the coming decades.